These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

875 related articles for article (PubMed ID: 34491575)

  • 1. Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.
    Sargin Altunok E; Satici C; Dinc V; Kamat S; Alkan M; Demirkol MA; Toprak ID; Kostek ME; Yazla S; Esatoglu SN
    J Med Virol; 2022 Jan; 94(1):291-297. PubMed ID: 34491575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
    Nachega JB; Ishoso DK; Otokoye JO; Hermans MP; Machekano RN; Sam-Agudu NA; Bongo-Pasi Nswe C; Mbala-Kingebeni P; Madinga JN; Mukendi S; Kolié MC; Nkwembe EN; Mbuyi GM; Nsio JM; Mukeba Tshialala D; Tshiasuma Pipo M; Ahuka-Mundeke S; Muyembe-Tamfum JJ; Mofenson L; Smith G; Mills EJ; Mellors JW; Zumla A; Mavungu Landu DJ; Kayembe JM
    Am J Trop Med Hyg; 2020 Dec; 103(6):2419-2428. PubMed ID: 33009770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
    Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
    Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
    Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
    Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: A retrospective study.
    Mousavi Movahed SM; Akhavizadegan H; Dolatkhani F; Nejadghaderi SA; Aghajani F; Faghir Gangi M; Ghazi Z; Ghasemi H
    J Med Virol; 2021 Jul; 93(7):4411-4419. PubMed ID: 33792956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU.
    Çalık Başaran N; Uyaroğlu OA; Telli Dizman G; Özışık L; Şahin TK; Taş Z; İnkaya AÇ; Karahan S; Alp Ş; Alp A; Metan G; Zarakol P; Sain Güven G; Öz ŞG; Topeli A; Uzun Ö; Akova M; Ünal S
    Turk J Med Sci; 2021 Apr; 51(2):411-420. PubMed ID: 32718127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.
    Pinzón MA; Ortiz S; Holguín H; Betancur JF; Cardona Arango D; Laniado H; Arias Arias C; Muñoz B; Quiceno J; Jaramillo D; Ramirez Z
    PLoS One; 2021; 16(5):e0252057. PubMed ID: 34033648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.
    Mortaz E; Bassir A; Dalil Roofchayee N; Dezfuli NK; Jamaati H; Tabarsi P; Moniri A; Rezaei M; Mehrian P; Varahram M; Marjani M; Mumby S; Adcock IM
    Int Immunopharmacol; 2021 Apr; 93():107407. PubMed ID: 33631512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
    Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
    J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in a cohort of COVID-19 Italian patients hospitalized during the first and second pandemic waves.
    Quaresima V; Scarpazza C; Sottini A; Fiorini C; Signorini S; Delmonte OM; Signorini L; Quiros-Roldan E; Imberti L
    Biol Sex Differ; 2021 Aug; 12(1):45. PubMed ID: 34380555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographics, clinical characteristics, and outcomes in hospitalized patients during six waves of COVID‑19 in Northern Iran: a large cohort study.
    Shirafkan H; Sadeghi F; Halaji M; Rahmani R; Yahyapour Y
    Sci Rep; 2023 Dec; 13(1):22527. PubMed ID: 38110656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
    Bokharee N; Khan YH; Khokhar A; Mallhi TH; Alotaibi NH; Rasheed M
    Expert Rev Anti Infect Ther; 2021 Oct; 19(10):1219-1244. PubMed ID: 33719819
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
    Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
    J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical outcomes, demographic, and laboratory characteristics of hospitalized COVID-19 patients during major three waves driven by Alpha, Delta, and Omicron variants in Tehran, Iran.
    Heydarifard Z; Shafiei-Jandaghi NZ; Safaei M; Tavakoli F; Shatizadeh Malekshahi S
    Influenza Other Respir Viruses; 2023 Aug; 17(8):e13184. PubMed ID: 37565071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation.
    Desai A; Santonocito OG; Caltagirone G; Kogan M; Ghetti F; Donadoni I; Porro F; Savevski V; Poretti D; Ciccarelli M; Martinelli Boneschi F; Voza A
    Medicina (Kaunas); 2020 Oct; 56(11):. PubMed ID: 33138045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.